Suchen
MoonLake Immunotherapeutics
MLTXZur Watchlist hinzufügen
18.937USD
-0.193-1.01%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.35BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MoonLake Immunotherapeutics Unternehmen
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics Informationen
BörsenkürzelMLTX
Name des UnternehmensMoonLake Immunotherapeutics
IPO-datumOct 20, 2020
CEOSantos Da Silva (Jorge)
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeOct 20
AddresseDorfstrasse 29
StadtZUG
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
Postleitzahl6300
Telefon41415108022
Websitehttps://moonlaketx.com/
BörsenkürzelMLTX
IPO-datumOct 20, 2020
CEOSantos Da Silva (Jorge)
Führungskräfte von MoonLake Immunotherapeutics
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von MoonLake Immunotherapeutics?
Die fünf größten Anteilseigner von MoonLake Immunotherapeutics sind: Dr. Kristian Reich
Wie viele Institutionen halten Anteile an MoonLake Immunotherapeutics (MLTX)?
Mit Stand vom 2026Q1 halten 358 Institutionen Anteile an MoonLake Immunotherapeutics, mit einem Gesamtmarktwert von etwa 54.44M, was 74.73% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3151979.00 gestiegen.